15th IPOS Debate on Screening for Distress by alex_j_mitchell in Rotterdam (Nov2013)
WUMC Master Facility Planning Clinical Administrator Committee April 24, 2012.
CORPORATE OVERVIEW TNIB is a late stage immunotherapy company with short term sustainable revenue delivering low cost, effective, safe immuno therapies.
UCCC Cancer Outcomes 2010
UCH: Cancer Outcomes 2011
Annual Report
